Streetbeat News

Stock Prices

IBCP

Independent Bank (NASDAQ:IBCP) reported Q3 2024 earnings per share of $0.81, surpassing the analyst estimate of $0.76. However, its sales of $41.854 million fell short of the expected $42.260 million. Despite this, sales increased by 6.16% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:06 pm

PSTX

Poseida Therapeutics is set to present new preclinical data on its non-viral gene editing treatment, P-KLKB1-101, for hereditary angioedema at the ACAAI 2024 Scientific Meeting. The data highlights the potential of their Cas-CLOVER™ system for effective and controlled gene editing.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:05 pm

AQST

Aquestive Therapeutics announced that its oral allergy syndrome challenge study for Anaphylm met both primary and secondary endpoints, indicating positive results for the treatment's efficacy.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:05 pm

CRS

Carpenter Technology reported its Q1 2025 financial results, with adjusted EPS of $1.73 beating the estimate of $1.59, but sales of $717.6 million missing the expected $742.96 million.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:04 pm

ITGR

Integer Holdings reported Q3 2024 adjusted EPS of $1.43, surpassing the estimate of $1.36. However, their sales of $431.417 million fell short of the expected $440.628 million.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:03 pm

XPRO

Expro Group's shares are trading higher following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:03 pm

NNE

NANO Nuclear Energy Inc. has announced a $36 million upsized underwritten public offering of 2,117,646 shares of common stock and warrants to purchase 1,058,823 shares. Each share and warrant is priced at $17.00. The offering includes a 30-day overallotment option for additional shares and warrants.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:02 pm

ARQT

Arcutis Biotherapeutics presented new data at the ACAAI 2024 meeting showing that ZORYVE cream 0.15% significantly improves atopic dermatitis symptoms and patient quality of life. The cream demonstrated rapid efficacy, with improvements in itch reduction and other symptoms within 24 hours.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:01 pm

MRNS

Marinus Pharmaceuticals announced that its Phase 3 TrustTSC trial of oral ganaxolone in treating Tuberous Sclerosis Complex did not meet its primary endpoint. The company is now exploring strategic alternatives and implementing cost reduction measures, including workforce cuts.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:01 pm

GES

Analysts' ratings for Guess (NYSE:GES) show a mix of bullish and indifferent sentiments, with a recent decrease in the average price target by 4.66%. Despite a 10.24% revenue growth, Guess faces challenges with low net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:01 pm